Kyntra Bio (NASDAQ:KYNB – Get Free Report) is one of 843 public companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare Kyntra Bio to related businesses based on the strength of its analyst recommendations, institutional ownership, risk, earnings, dividends, profitability and valuation.
Profitability
This table compares Kyntra Bio and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kyntra Bio | 2,199.13% | N/A | -47.27% |
| Kyntra Bio Competitors | -12,224.09% | -202.33% | -31.23% |
Valuation & Earnings
This table compares Kyntra Bio and its competitors gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Kyntra Bio | $4.62 million | $183.45 million | 0.07 |
| Kyntra Bio Competitors | $768.41 million | $11.71 million | -18.32 |
Kyntra Bio’s competitors have higher revenue, but lower earnings than Kyntra Bio. Kyntra Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a summary of recent ratings and target prices for Kyntra Bio and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kyntra Bio | 1 | 1 | 5 | 0 | 2.57 |
| Kyntra Bio Competitors | 9923 | 15317 | 45694 | 1603 | 2.54 |
Kyntra Bio presently has a consensus price target of $36.80, suggesting a potential upside of 1,055.42%. As a group, “Biotechnology” companies have a potential upside of 131.06%. Given Kyntra Bio’s stronger consensus rating and higher probable upside, research analysts plainly believe Kyntra Bio is more favorable than its competitors.
Volatility and Risk
Kyntra Bio has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Comparatively, Kyntra Bio’s competitors have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.
Institutional & Insider Ownership
72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Kyntra Bio beats its competitors on 9 of the 13 factors compared.
About Kyntra Bio
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.
